Applied Biosystems (ABI) Release: Joint Research Study Reports Discovery Of New Set Of Potential Prognostic Biomarkers In Early Stage Breast Cancer At Human Genome Organization, The (HUGO)
10/19/2005 5:11:08 PM
KYOTO, Japan--(BUSINESS WIRE)--April 21, 2005--
Applied Biosystems Gene Expression Products and PANTHER(TM) Protein Classification System Reveal Distinct Molecular Mechanisms Predicting Tumor Malignancy at Early Stage in Different Subtypes of Breast Cancer
Scientists from a joint research study conducted by Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, and the Norwegian Radium Hospital will today report the discovery of a new set of potential prognostic biomarkers for early stage breast cancer at the Human Genome Organization (HUGO) 10th Annual Human Genome Meeting in Kyoto, Japan.
Using Applied Biosystems Expression Array System and Human Genome Survey Microarray, researchers identified a set of 54 genes with the greatest prognostic value for breast cancer and discovered that tumor aggressiveness may be determined at early stage in different subtypes of breast cancer. Findings suggest that these subtypes of breast cancer represent biologically distinct diseases and substantiate the value of gene expression-based subtypes in the prognosis and diagnosis of breast cancer at an early stage.